Echo IQ (ASX:EIQ) requested a pre-submission meeting with the US Food and Drug Administration (FDA) to confirm the design of a proposed validation trial of its heart failure screening tool, EchoSolv HF, according to a Tuesday filing with the Australian bourse.
The meeting, expected within 90 days, follows two completed clinical studies that showed that EchoSolv HF's artificial intelligence (AI) technology detected 86% of heart failure cases, compared with a 46% detection rate in standard clinical practice, the filing said.
The company aims to use the meeting to confirm its validation study design with the US FDA and expects regulatory clearance for EchoSolv HF in the second half of 2025.
The AI and medical technology company is in advanced talks with US healthcare organizations to conduct the validation study, set to start next quarter as the final step before FDA submission.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。